TY - JOUR
T1 - Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C
AU - Moritou, Yuki
AU - Ikeda, Fusao
AU - Iwasaki, Yoshiaki
AU - Baba, Nobuyuki
AU - Takaguchi, Kouichi
AU - Senoh, Tomonori
AU - Nagano, Takuya
AU - Takeuchi, Yasuto
AU - Yasunaka, Tetsuya
AU - Ohnishi, Hideki
AU - Miyake, Yasuhiro
AU - Takaki, Akinobu
AU - Nouso, Kazuhiro
AU - Yamamoto, Kazuhide
N1 - Funding Information:
This work was supported in part by the Research Program of Intractable Disease sponsored by the Ministry of Health, Labor, and Welfare of Japan, and by a Grant-in-Aid (22590733) for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to Y. I.). We thank Chizuru Mori for technical assistance and Toshie Ishi for valuable help in data collection.
PY - 2013
Y1 - 2013
N2 - The impact of single-nucleotide polymorphisms (SNP) of patatin-like phospholipase domaincontaining protein 3 (PNPLA3) on development of hepatocellular carcinoma (HCC) is not clarified for Japanese patients with chronic hepatitis C. The present study investigated the associations of rs738409 PNPLA3 with HCC development after the antiviral therapy with peg-interferon and ribavirin for Japanese patients with hepatitis C virus serotype 1 and high viral load. Of the 271 patients enrolled in the study, 20 patients developed HCC, during a median follow-up period of 4.6 years. Multivariate analysis in the proportional hazards models revealed that sex, body mass index, platelet counts, and alpha feroprotein (AFP) had significant associations with HCC development (p = 0.011, 0.029, 0.0002, and 0.046, respectively). Multivariate regression analysis revealed that PNPLA3 148 M was significantly associated with serum AFP level (p = 0.032), other than body mass index, platelet count, and alanine aminotransferase (p = 0.0006, 0.0002, and 0.037, respectively), and that serum AFP level was significantly associated with PNPLA3 148 M (p = 0.017). Serum AFP level is an important factor in predicting HCC development after the antiviral therapy for Japanese patients with chronic hepatitis C, the mechanism of which might involve its significant associations with the SNP genotype of PNPLA3.
AB - The impact of single-nucleotide polymorphisms (SNP) of patatin-like phospholipase domaincontaining protein 3 (PNPLA3) on development of hepatocellular carcinoma (HCC) is not clarified for Japanese patients with chronic hepatitis C. The present study investigated the associations of rs738409 PNPLA3 with HCC development after the antiviral therapy with peg-interferon and ribavirin for Japanese patients with hepatitis C virus serotype 1 and high viral load. Of the 271 patients enrolled in the study, 20 patients developed HCC, during a median follow-up period of 4.6 years. Multivariate analysis in the proportional hazards models revealed that sex, body mass index, platelet counts, and alpha feroprotein (AFP) had significant associations with HCC development (p = 0.011, 0.029, 0.0002, and 0.046, respectively). Multivariate regression analysis revealed that PNPLA3 148 M was significantly associated with serum AFP level (p = 0.032), other than body mass index, platelet count, and alanine aminotransferase (p = 0.0006, 0.0002, and 0.037, respectively), and that serum AFP level was significantly associated with PNPLA3 148 M (p = 0.017). Serum AFP level is an important factor in predicting HCC development after the antiviral therapy for Japanese patients with chronic hepatitis C, the mechanism of which might involve its significant associations with the SNP genotype of PNPLA3.
KW - HCC
KW - HCV
KW - Interferon
KW - PNPLA3
UR - http://www.scopus.com/inward/record.url?scp=84878773083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878773083&partnerID=8YFLogxK
U2 - 10.1186/2193-1801-2-251
DO - 10.1186/2193-1801-2-251
M3 - Article
AN - SCOPUS:84878773083
SN - 2193-1801
VL - 2
JO - SpringerPlus
JF - SpringerPlus
IS - 1
ER -
